Amount of cash payable upon the achievement of certain milestones based on the foreclosure sale agreement.

No definition available.

Name:	mcet_CashPayableUponMilestones
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Description of future royalties milestone payments having an initial or remaining terms in excess of one year.

+ References

No definition available.

+ Details

Name:	mcet_FutureRoyaltiesMilestonePaymentsDescription
Namespace Prefix:	mcet_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate amount to become due and payable in case of failure to achieve any of the milestones.

+ References

No definition available.

+ Details

Name:	mcet_TotalCashPayableUponMilestones
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of unpaid license fees related to the termination of license agreement.

+ References

No definition available.

+ Details

Name:	mcet_UnpaidLicenseFees
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of unpaid patent costs related to the termination of license agreement.

+ References

No definition available.

+ Details

Name:	mcet_UnpaidPatentCosts
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of all assets obtained in full or partial satisfaction of a debt arrangement through foreclosure proceedings or defeasance; includes real and personal property; equity interests in corporations, partnerships, and joint ventures; and beneficial interests in trusts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28367877&loc=d3e4437-111522

+ Details

Name:	us-gaap_ForeclosedAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name:	us-gaap_InterestReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndMaintenanceRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	mcet_LicenseAgreementAxis=mcet_ForeclosureSaleAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mcet_RutgersLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mcet_CorningIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mcet_PfizerIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2010	Feb. 28, 2015	Feb. 28, 2014	May 09, 2014	Nov. 30, 2014
Rutgers License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Unpaid License Fees				$ 25,000
Unpaid Patent Costs				75,665
Accrued Interest				8,375
Foreclosure Sale Agreement [Member] \| Xenogenics [Member]
Deferred Revenue Arrangement [Line Items]
Cash Payments For Purchase Of Assets	400,000
Total Cash Payable Upon Milestones		4,300,000
Foreclosure Sale Agreement [Member] \| Xenogenics [Member] \| Milestone One [Member]
Deferred Revenue Arrangement [Line Items]
Cash Payable Upon Milestones	300,000
Future Royalties Milestone Payments Description	(i) initiation of pivotal Generation 2 stent human clinical trials, (ii) execution of an agreement in which Xenogenics grants a third party rights to develop or exploit the purchased assets, valued at no less than $3,000,000 (including all up-front payments and the net present value of any future royalty/milestone payments), and (iii) a change of control of Xenogenics;
Foreclosure Sale Agreement [Member] \| Xenogenics [Member] \| Milestone Two [Member]
Deferred Revenue Arrangement [Line Items]
Cash Payable Upon Milestones	1,000,000
Future Royalties Milestone Payments Description	(i) regulatory approval by any regulatory authority in a European Union member country, (ii) execution of an agreement in which Xenogenics grants a third party rights to develop or exploit the purchased assets, valued at no less than $5,000,000 (including all up-front payments and the net present value of any future royalty/milestone payments); and (iii) a change of control of Xenogenics;
Foreclosure Sale Agreement [Member] \| Xenogenics [Member] \| Milestone Three [Member]
Deferred Revenue Arrangement [Line Items]
Cash Payable Upon Milestones	3,000,000
Future Royalties Milestone Payments Description	(i) regulatory approval by the U.S. Food and Drug Administration, (ii) execution of an agreement in which Xenogenics grants a third party rights to develop or exploit the purchased assets, valued at no less than $5,000,000 (including all up-front payments and the net present value of any future royalty/milestone payments); and (iii) a change of control of Xenogenics.
Corning Incorporated [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Revenue Recognized		11,029	11,029
Deferred Revenue		422,794			433,824
Corning Incorporated [Member] \| Execution Of Licence Agreement [Member]
Deferred Revenue Arrangement [Line Items]
License and Maintenance Revenue		375,000
Corning Incorporated [Member] \| Completion Of Licence Agreement [Member]
Deferred Revenue Arrangement [Line Items]
License and Maintenance Revenue		375,000
Pfizer Incorporated [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Revenue Recognized		1,300	1,300
Deferred Revenue		$ 14,300			$ 15,600